Phase III, randomized, observer-blind, placebo-controlled, multi-center, multinational study to evaluate the efficacy, immunogenicity, and safety of a Respiratory Syncytial Virus vaccine in infants and toddlers (PEARL).
This study will evaluate the safety and immune response of a new candidate RSV vaccine in infants and toddlers.
Principal Investigator:
Point of Contact: